Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase Ib/IIa study of TQA3038 injection in chronic hepatitis B
CTR20241960Phase 2Active
- Sponsor
- Chia Tai-Tianqing Pharmaceutical Group
- Start
- Jul 2024
- Modality
- Vaccine mRNA → mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
Phase 2, double-blind trial of TQA3038 in Chronic Hepatitis B (CHB) (4 arms), sponsored by Chia Tai-Tianqing Pharmaceutical Group. Started Jul 2024; status: active.
02
Drugs
TQA3038
03
Conditions
Chronic Hepatitis B (CHB)
Beyond the preview
Go deeper on CTR20241960.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20241960.